Прямой ингибитор ренина алискирен: новые горизонты нефропротекции

1. Мухин Н.А., Фомин В.В., Моисеев С.В. Микроальбуминурия – универсальный маркер неблагоприятного прогноза. Клин. мед. 2008; 11: 4–9.
2. Мухин Н.А. Снижение скорости клубочковой фильтрации – общепопуляционный маркер неблагоприятного прогноза. Тер. арх. 2007; 6: 5–10.
3. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.
4. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.
5. Rossing P, Hommel E, Smidt UM, Parving H-H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511–6.
6. de Zeeuw D, Remuzzi G, Parving H-H et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309–20.
7. de Zeeuw D, Remuzzi G, Parving H-H et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921–7.
8. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198–202.
9. Pimenta E, Oparil S. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Ther Clin Risk Manag 2009; 5: 459–64.
10. Wiggins KJ, Kelly DJ. Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors? Kidney Int 2009; 76 (1): 23–31.
11. Sureshkumar KK. Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy. Vasc Health Risk Manag 2008; 4 (6): 1205–20.
12. Feldman DL. New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease. Hypertens Res 2010; 33: 279–87.
13. Jerums C, Premaratne E, Panagiotopoulos S et al. New and old markers of progression of diabetic nephropathy. Diabet Res Clin Pract 2008; 82 (Suppl. 1): S30–7.
14. MacIsaac RJ, Jerums G. Albuminuric and non-albuminuric pathways to renal impairment in diabetes. Minerva Endocrinol 2005; 30 (3): 161–77.
15. Мухин Н.А., Тареева И.Е., Шилов Е.М., Козловская Л.В. Диагностика и лечение болезней почек. М.: ГЭОТАР-Медиа, 2008.
16. Mogensen CE Twelve shifting paradigms in diabetic renal disease and hypertension diabetes research and clinical practice. Diabet Res Clin Pract 2008; 82 (Suppl. 1): 2–9.
17. Rigalleau V, Lasseur C, Raffaitin C et al. Normoalbuminuric renal-insufficient diabetic patients: a lower-risk group. Diabet Care 2007; 30 (8): 2034–9.
18. Yokoyama H, Sone H, Oishi M et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 2009; 24 (4): 1212–9.
19. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabet Care 2004; 27: 195–200.
20. Garg AX, Kiberd BA, Clark WF et al. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int 2002; 61 (6): 2165–75.
21. Foster MC, Hwang SL, Larson MG et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med 2007; 167: 1386–92.
22. MacIsaac R, Panagiotopoulos S, McNeil K et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabet Care 2006; 29: 1560–6.
23. Mazzali M, Kanellis I, Han L et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: 991–7.
24. Navarro J, Mora-Fernandez C. The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications, Cytocine Growth Factor Rev 2006; 17: 441–50.
25. Niewczas M, Ficociello L, Johnson A et al. Serum concentrations of markers of TNFa and Fas-mediated pathways and renal function in non-proteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009; 4 (1): 62–70.
26. Kumar D, Robertson S, Burns K. Evidence of apoptosis in human diabetic kidney. Mol Cell Biochem 2004; 259: 67–70.
27. Peixoto AJ, Orias M. Is there a role for direct renin inhibitors in chronic kidney disease? Curr Opin Nephrol Hypertens 2009; 18: 397–403.
28. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE). Lancet 2003; 361 (9352): 117–24.
29. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321 (7274): 1440–4.
30. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008; 372 (9638): 547–53.
31. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3 (9): 486–92.
32. Yasmin P, Gusbeth-Tatomir P, Covic A, Goldsmith D. Direct renin inhibitors: ONTARGET for success? Int Urol Nephrol 2009; 41: 341–55.
33. Чазова И.Е., Фомин В.В., Пальцева Е.М. Прямой ингибитор ренина алискирен – новые возможности защиты почек при артериальной гипертензии. Клин. нефрол. 2009; 1: 44–9.
34. Schmieder RE, Philipp T, Guerediaga J et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren, a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009; 27; 119 (3): 371–3.
35. Dahlof B, Anderson DR, Arora V et al. Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension. J Clin Hypertens 2007; 9 (Suppl. A): A157.
36. Uresin Y, Taylor AA, Kilo C et al. Efficacy and safety of the direct rennin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8 (4): 190–200.
37. Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008; 51: 519–28.
38. Andersen K. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26: 589–99.
39. Strasser RH, Puig JG, Farsang C et al. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 2007; 21 (10): 766–9.
40. Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 1; 111 (8): 1012–8.
41. Oparil S, Yarows SA, Patel S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370 (9583): 221–9.
42. Drummond W, Munger MA, Rafique Essop M et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007; 9 (10): 742–50.
43. Duprez DA, Munger MA, Botha J et al. The AGELESS Study: the effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients 65 years of age with systolic hypertension. Abstract 4423. Circulation 2008; 118: S886–7.
44. ALLAY Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530–7.
45. Recio-Mayoral A, Kaski JC, McMurray JJ et al. Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovasc Drugs Ther 2007; 21 (6): 459–65.
46. Lu H, Rateri DL, Feldman DL et al. Renin inhibition reduces hypercholesterolemia – induced atherosclerosis in mice. J Clin Invest 2008; 118: 984–93.
47. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–46.
48. Lansang MC, Osei SY, Price DA et al. Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan. Hypertension 2000; 36: 834–8.
49. Fisher N, Allan D, Kifor I et al. Responses to converting enzyme and renin inhibition. Role of Angiotensin II in human. Hypertension 1994; 23: 44–51.
50. Carey RM. Antihypertensive and renoprotective mechanisms of renin inhibition in diabetic rats. Hypertension 2008; 52 (1): 63–4.
51. Kelly DJ, Zhang Y, Moe G et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50: 2398–404.
52. Pilz B, Shagdarsuren E, Wellner M et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46: 569–76.
53. Persson F, Rossing P, Reinhard H et al. Renoprotective effects of direct renin inhibition compared to and in combination with maximum recommended dose of irbesartan in patients with type 2 diabetes and albuminuria. Kidney Int 2008; 73: 1419–25.
54. Parving HH, Brenner B., McMurray JJV et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24 (5): 1663–71.

С.В.Виллевальде, Е.А.Троицкая, Ж.Д.Кобалава

Российский университет дружбы народов, Москва

________________________________________________

S.V. Villevalde, E.A. Troitskaya, Zh.D. Kobalava

Russian University of Peoples’ Friendship, Moscow